قالب وردپرس درنا توس
Home / Business / Life science company BioAgilytix will add 878 jobs in Durham and invest US$61.5 million

Life science company BioAgilytix will add 878 jobs in Durham and invest US$61.5 million



Research Triangle Park – BioAgilytix is ​​one of North Carolina’s fastest-growing local life science companies. It invested $61.5 million in its Durham global headquarters and added 878 new employees.

The company executives said the company currently has about 300 employees in Durham, and the total number of new positions may actually be higher.

The company announced on Thursday morning that the company will create a variety of jobs, and the average annual salary will be approximately $95,000.

The fast-growing company provides contract bioanalytical testing for other companies’ macromolecular drug candidates. The company today announced the expansion, which is the latest development in North Carolina’s exciting life sciences trajectory.

“Through strong cooperation with the state government under the leadership of Governor Cooper and Secretary of State Cooperland, we decided to spend tens of millions of dollars to expand our team and facilities in Durham County,”

; said Jim Datin, CEO of BioAgilytix. “And, more importantly, the area has a wealth of life science expertise and a great place to live. Since our establishment, this visit to outstanding talent has allowed us to flourish in North Carolina.

Scientists working in BioAgilytix laboratories. (Photo by BioAgilytix)

Tax incentives

If the new work goals are achieved, the company will receive $18 million in a 12-year employment development investment grant from North Carolina.

Macromolecular drugs, commonly referred to as therapeutic proteins or biological drugs, include amino acid-based molecules, ranging in size from small peptides to large proteins (such as monoclonal antibodies). Macromolecular drugs usually contain 5,000 to 50,000 atoms per molecule and usually require intravenous infusion.

In contrast, small-molecule drugs are “traditional” compounds created in the laboratory, usually with 20 to 100 atoms. Robin Deacle, vice president of corporate communications at the Biotechnology Center, reports that they are generally very suitable for oral administration.

Governor Roy Cooper (Roy Cooper) said in a statement: “North Carolina is a world-class location for companies that lead research and development work that can treat and prevent diseases such as the coronavirus.” “Like BioAgilytix. Of companies are expanding here because they know that North Carolina can provide a stable business environment for skilled workers. Even during the global health crisis, they need a successful and stable business environment.”

The privately held BioAgilytix was founded in 2008 by biochemist and serial entrepreneur Dr. Afshin Safavi. It has grown rapidly, from the initial three employees to 425 employees today.It was acquired by two private equity firms in 2018: Cobepa, a US$3 billion euro fund based in Belgium and founded by Dennis Gillings, the father of the contract research industry in North Carolina and former Quintiles founder and chairman Dennis Gillings GHO Capital, London Fund, PhD


BioAgilytix’s global headquarters in Durham. (Photo by BioAgilytix)

Who is BioAgilytix?

Our CRO laboratory services support all bioanalytical needs from discovery to pre-clinical and clinical development, manufacturing and post-market surveillance under non-GLP, GLP spirit, GLP, GCP or GMP. We are capable of cooperating with sponsors in the US headquarters in North Carolina, the European headquarters in Hamburg, Germany, and today the Boston Laboratory at the Biotechnology Innovation Center.

In all of our locations, our scientists excel in areas that require scientific requirements for analysis and development, and can use our extensive technology selection kit to develop customized analysis methods and pair them with the best platform. Whether it is for the identification and verification of tests, sample analysis, or batch endorsement testing for production, BioAgilytix adheres to the same commitment to quality to ensure efficient, accurate and highest performance standards.

Our laboratory services also surpass our core competence and technology, because our employees are strictly trained and very competent, and we use each of their skills to meet the needs of our customers. This allows us to provide a wide range of support services that can be used as a supplement to your existing projects or for independent evaluation. These services include spectroscopy, colorimetric analysis, HPLC, etc.

Source: BioAgilytix


BioAgilytix has laboratories in Durham, Boston, and Hamburg, Germany, and provides contract services for international pharmaceutical and biotechnology companies.

In August, BioAgilytix and Brio Systems of Boston launched a platform to provide US employers with a comprehensive COVID-19 testing program.

Recent WRAL TechWire headlines about BioAgilytix

Durham’s BioAgilytix partners with Boston companies to help employers test for COVID-19

Durham-based BioAgilytix acquires Massachusetts-based biomedical company

Belgian investment company acquires Durham bio-testing company BioAgilytix




Source link